Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.510.47%
QQQ
717.320.05%
BTC/USD
79432.922.2678%
DIA
533.350.67%
GLD
407.130.75%
TLT
82.230.2%

HeartSciences Inc

HSCSNASDAQ
Trade with Public
Trade with Public
$3.35
-0.01-0.3%
Last update: Sep 4, 9:29 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

HeartSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for HeartSciences (HSCS).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$10Upside to Avg. PT+198.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 24, 2026Ascendiant CapitalLucas WardPT CutBuy$9→$8
Dec 22, 2025Ascendiant CapitalLucas WardPT RaiseBuy$9→$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Raises Price Target to $9.2

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and raises the price target from $9 to $9.2.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $9

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $9.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $14

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $14.
Benzinga Newsdesk

PRO
Maxim Group Reiterates Buy on HeartSciences, Maintains $12 Price Target

Maxim Group analyst Allen Klee reiterates HeartSciences (NASDAQ:HSCS) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
Ascendiant Capital Reiterates Buy on Heart Test Laboratories, Maintains $15 Price Target

Ascendiant Capital analyst Lucas Ward reiterates Heart Test Laboratories (NASDAQ:HSCS) with a Buy and maintains $15 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved